** Shares of biotech firm Patrys fall 50% to A$0.003, a record low
** Stock posts biggest intraday pct fall since Nov. 11, 2008
** Co says cancer therapy antibody PAT-DX1 did not pass some parameters in production
** Adds, it will not use the produced batch for planned Phase-1 clinical trial in cancer patients
** Says it will now pivot towards developing therapeutic possibilities for its other antibody, PAT-DX3
** About 24 mln shares change hands, ~28x the 30-day avg volume
** PNB down ~63% YTD
(Reporting by Kumar Tanishk in Bengaluru)
((Tanishk.Kumar@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.